All In Biotech

Drug Trial Radar · NCT06866691

Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide

Seizure Prevention in Traumatic Brain Injury: A Comparative Effectiveness Study of Levetiracetam and Lacosamide

Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Apr 18, 2025

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Wake Forest University Health SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the incidence of early post-traumatic seizures. The study will also assess the benefit of lacosamide compared to levetiracetam in regards to agitation and behavioral adverse effects in patients with traumatic brain injury requiring seizure prophylaxis.

Conditions

  • Traumatic Brain Injury

Interventions

  • levetiracetamDrug

    levetiracetam 1000 mg intravenously or by mouth twice daily for a total of 7 days

  • lacosamideDrug

    lacosamide 200 mg intravenously or by mouth twice daily for a total of 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Early Post-traumatic SeizureTime frame: Up to day 7 post injury

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.